Biohaven Pharmaceutical Hld

Biohaven Ltd. operates as a biopharmaceutical company that focuses on neurological and neuropsychiatric diseases. Its portfolio includes treatments for medical needs including focal epilepsy, obsessive compulsive disorder, spinocerebellar ataxia and spinal muscular atrophy. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Appian

Find out how the rest of the markets are behaving.

2 Extraordinary Events Sent These 2 Stocks Soaring Tuesday

Pfizer

Pfizer Inc. agreed to buy the rest of Biohaven Pharmaceutical Holding Co. for about $11.6 billion, deploying its pile of cash earned from Covid-19 sales to acquire a new migraine drug.

Pfizer to buy rest of Biohaven for $11.6B

Pfizer Inc (NYSE:PFE) has agreed a US$11.6bn offer for Biohaven Pharmaceutical Holding Co (NYSE:BHVN), which has reignited talk that more mergers and acquisitions (M&A) could be around the corner in the biotech sector.  The takeover has been struck for US$148.5 of cash per share, a 78% premium to the last closing price.

Pfizer splashes $11.6bn of vaccine cash on Biohaven Pharmaceutical Holding

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -17.86% and 70.40%, respectively, for the quarter ended March 2022.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates

Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) for $148.50 per share, equivalent to $11.6 billion.  Pfizer will also make payments at closing to settle Biohaven's third-party debt and for the redemption of all.

Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) to Pfizer Inc. for $148.50 per share in cash is fair to Biohaven shareholders. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven's non-CGRP development stage pipeline compounds, per Biohaven common share. Halper Sadeh encourag

BHVN Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Biohaven Pharmaceutical Holding Company Ltd. Is Fair to Shareholders

Shares of Biohaven soared following the announcement.

Pfizer to Buy Biohaven Pharmaceuticals for $11.6 Billion

(Reuters) -Pfizer Inc said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding Company Ltd for about $11.6 billion in cash.

Pfizer to buy Biohaven Pharmaceutical in $11.6 billion deal

Pfizer Inc. PFE, -0.82% said Tuesday it has entered a definitive agreement to acquire Biohaven Pharmaceutical Holding Company Ltd. BHVN, -7.88% for $11.6 billion in cash.

Pfizer to acquire Biohaven Pharma for $11.6 billion in cash sending Biohaven shares up 74% premarket

Pfizer Inc. (NYSE: PFE) announced it is buying Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) in a deal valued at $11.6 billion in cash.

Why Pfizer (PFE) Is Buying Biohaven Pharmaceutical (BHVN) For $11.6 Billion In Cash

Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven Record reported revenues of $319 million NURTEC® ODT (rimegepant) TRx volumes grew 8% versus the fourth quarter and net product revenue was $124 million for the first quarter of 2022 Net product sales guidance of $825 - $900 million provided for 2022 Received EU approval from the European Commission ("EC") for rimegepant 75 mg for the acute and preventive treatment of migraine; EC marketing authorization valid in all 27 member countries of the European Union Expanded payer coverage for NURTEC ODT, extending coverage to 96 percent of total commercial lives and approximately 263 million people in all payer channels Featured 13 abstracts, including two oral presentations, at the 2022 American Academy of Neurology Annual Meeting, notably highlighting NURTEC ODT's clinical utility as demonstrated by a reduction in opioid prescriptions filled and medication overuse headache following treatment U.S. Food and Drug Administration ("FDA") approved NURTEC ODT label amendment to include clinical lactation data Initiated enrollment in two new Phase 2/3 clinical trials assessing the safety and efficacy of NURTEC ODT 75 mg in patients with sinusitis and temporomandibular disorder NEW HAVEN, Conn.

Biohaven Reports First Quarter 2022 Financial Results and Reports Recent Business Developments

NEW YORK & NEW HAVEN, CONN.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Biohaven not alread

Pfizer to Acquire Biohaven Pharmaceuticals

NEW HAVEN, Conn. , May 9, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022

Biohaven Pharmaceutical (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Biohaven Pharmaceutical (BHVN) This Earnings Season?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Biohaven Pharmaceutical Holding Company Ltd. ( BHVN , Financial) recently shrugged off concerns about its lack of transparency on sales of its only commercial product after investors punished the company's shares.

Biohaven Shares Drop Over Uncertainty About Nurtec Sales

NEW YORK & NEW HAVEN, Conn.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month. VYDURA®, an orally disintegrating

Pfizer and Biohaven's VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine

More than 25% of patients reported being severely or very severely impacted by their migraine attacks Study showed higher levels of migraine-related disability were associated with increased HCRU costs in primary care and specialty settings among adults with episodic migraine Data suggests that assessment of disability in people with migraine may support prescribing of cost-effective interventions, particularly among those with severe disability NEW HAVEN, Conn., April 14, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Real-World Study Highlights Increased Healthcare Utilization Among Americans with Episodic Migraine having Higher Levels of Migraine-Related Disability

- Insurance Coverage of Nurtec ODT Now Totals 96 Percent of Commercial Lives or Approximately 255 Million Lives Covered in All Channels - Nurtec ODT Label Expanded to include Lactation Data in the Prescribing and Patient Information for Breastfeeding Mothers NEW HAVEN, Conn. , April 14, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update

Biohaven Pharmaceutical has a significant portfolio of innovative product candidates across neurological and neuropsychiatric diseases. The company's product, NURTEC ODT, is the first and only therapy approved by FDA to both treat and prevent migraine attacks.

Biohaven Pharmaceutical: Recent Growth Will Continue

Longitudinal medical and prescription claims were used to assess opioid prescriptions and MME's dispensed amongst migraine patients nine months prior to and nine months following Nurtec® ODT initiation.   Among the 14,019 with migraine who used opioids prior to initiating treatment with Nurtec ODT, approximately 41% had no opioid Rx fills in the 9 months following initiation.

Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec® ODT Therapy: A Real-World Administrative Claims Analysis

NHF's Veterans/Military Outreach Program aims at raising awareness of migraine in this high-risk population Sponsorship adds to existing Biohaven programs supporting active-duty service members, veterans and their families with migraine NEW HAVEN, Conn., April 6, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Expands Commitment to Supporting Veterans and Military Through Sole Sponsorship of National Headache Foundation's (NHF) Outreach Program

NEW HAVEN, Conn. , April 1, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Nurtec (rimegepant) Lactation Clinical Study Published in Breastfeeding Medicine Journal

Migraine patients treated with Nurtec ODT had a reduction in total opioid prescriptions filled after initiation of therapy, according to an analysis of real-world administrative claims Single and multiple daily doses of intranasal zavegepant of up to 40 mg were well tolerated in Phase 1 study Rimegepant, atogepant and monoclonal antibody treatments determined to be effective options for the prevention of migraine when compared vs placebo NEW HAVEN, Conn. , March 31, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Data at 2022 American Academy of Neurology (AAN) Annual Meeting Demonstrate Leadership in Migraine and Commitment to Advancing Potential New Therapeutic Options in Neurological Diseases

Biohaven Pharmaceutical Holding Company Ltd. ( BHVN , Financial) and its shareholders could be in for a pleasant surprise if the company's failed Alzheimer's drug proves effective in treating a rare disease.

News for Biohaven Pharmaceutical Hld Stock (BHVN)